Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants

The recruitment status of this study is unknown because the information has not been verified recently.

Verified December 2005 by Bnai Zion Medical Center. Recruitment status was Not yet recruiting

First Received on December 5, 2005. No Changes Posted

Sponsor:	Bnai Zion Medical Center
Information provided by:	Bnai Zion Medical Center
ClinicalTrials.gov Identifier:	NCT00261937

Purpose

We hypothesize that inhaled Furosemide will be an effective treatment in infants with acute bronchiolitis.

Condition	Intervention	Phase
Bronchiolitis	Drug: Inhaled Furosemide vs Placebo (Normal Saline)	Phase I

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment
Official Title:	Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants

Resource links provided by NLM:

Drug Information available for: Furosemide

U.S. FDA Resources

Further study details as provided by Bnai Zion Medical Center:

Primary Outcome Measures:

Clinical respiratory effects

Secondary Outcome Measures:

1. The duration of hospitalization
2. Time weaned off oxygen
3. Time to full enteral feeding

Study Start Date:	December 2005
Estimated Study Completion Date:	April 2006

Eligibility

Ages Eligible for Study:	up to 12 Months
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age: 0-12 months.
Infants who are otherwise healthy
Infants with chronic lung disease of prematurity (BPD) will be included, but will be analyzed separately.
Parents signed a written informed consent.

Exclusion Criteria:

• Other previous or co-morbidity, specifically: respiratory (other than BPD, like Asthma or Cystic Fibrosis), cardiac or renal disease or anomaly.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00261937

Contacts

Contact: Amir Kugelman, MD

972-4-8345397

dramir@netvision.net.il

Locations

Israel
Bnai Zion Medical Center and Naharia Galilli Medical Center	Not yet recruiting
Haifa, Israel, 31048
Contact: Amir Kugelman, MD 972-4-8345397 dramir@netvision.net.il

Sponsors and Collaborators

Bnai Zion Medical Center

Investigators

Principal Investigator:

Amir Kugelman

Bnai Zion Medical Center

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00261937 History of Changes
Other Study ID Numbers:	67/05
Study First Received:	December 5, 2005
Last Updated:	December 5, 2005
Health Authority:	Israel: Ministry of Health

Additional relevant MeSH terms:

Bronchiolitis
Bronchiolitis, Viral
Bronchitis
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Virus Diseases
Furosemide

Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 12, 2012